Objective: To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)-associated progressive multifocal leukoencephalopathy (PML).
outcome. 1 To limit infection in the brain, the rapid restoration of immunosurveillance is encouraged by interrupting the treatment and accelerating the removal of plasma NTZ, which is biologically active for up to 3 months after its infusion, with plasmapheresis (PLEX), which exchanges the plasma with donor plasma or albumin. Although the effectiveness of PLEX and the optimum treatment regimen have never been systematically investigated, PLEX is usually highly recommended in the management of NTZ-PML. 2, 3 Although effective in removing NTZ, PLEX might be detrimental for patient outcome, increasing the likelihood of the development of immune reconstitution inflammatory syndrome (IRIS) and of inflammatory brain damage 4 from the rapid restoration of immunosurveillance.
In this study, we retrospectively analyzed 193 international NTZ-PML cases reported in the literature and 34 Italian NTZ-PML cases with the aim of estimating the risk/benefit profile of PLEX in NTZ-PML.
METHODS PubMed search. We searched PubMed for
English articles that were published from January 2005 to June 2015 and that included the terms natalizumab and progressive multifocal leukoencephalopathy. We found 487 articles. Subsequently, we selected only those articles that reported clinical descriptions of the NTZ-PML patients, regardless of the original aim of the study. Articles lacking meaningful clinical information about the patients' PML diagnosis, treatments, and outcome, as well as articles about patients without MS (e.g., Crohn disease) who were treated with NTZ, were excluded. Patients described by multiple articles were listed once in the database with the most informative article listed as the source document. We excluded the following: cases and clinical series with suspected overlap between articles, previously published, Italian patients who were already included in the Italian dataset, and case series from which individual clinical information could not be extracted.
International published cases. A final sample of 193 international NTZ-PML cases, collected from 49 articles, e1-e44,5-9 was included in this study. All of the cases fulfilled the PML diagnostic criteria suggested by Berger et al. 10 For each case, we extracted the following demographic and clinical information: sex (male/female), age at time of PML diagnosis (years), country (Europe, United States, or rest of the world [ROW]), Expanded Disability Status Scale (EDSS) score prior to PML diagnosis, prior immunosuppressant exposure (yes/no), number of NTZ infusions at time of PML diagnosis, presence of symptoms at PML diagnosis (yes/no), PML lesion localization at diagnosis (supratentorial/infratentorial/both), CSF-JCV status at diagnosis (positive/negative), number of CSF-JCV copies (anytime; i.e., first CSF-JCV-positive PCR), PLEX treatment (yes/ no), additional treatments (mefloquine, mirtazapine, both, none), PML-IRIS development (yes/no), interval between PML Outcome variables. For the primary outcome measures, we examined survival and post-PML clinical status. Nonsurvivors were patients who died at any time due to PML complications after being diagnosed with PML (e.g., 1 Italian patient died because of cholecystitis that was unrelated to the PML, and, therefore, he was considered a survivor). The post-PML clinical status was compared to the PML clinical status at the diagnosis and rated as stable, improved, worsened, or dead based on the reported clinical descriptions, EDSS/Karnofsky Performance Scale scores, or authors' statements. The post-PML neurologic evaluation that was last available at the time of the writing of each article was used. Any stated change in disability was considered a clinical impairment/ worsening, regardless of the magnitude of the effect.
The median interval of follow-up (months) between PML diagnosis and the last available evaluation or outcome reached (e.g., death), whichever came first, is specified in table 1. For the Italian cohort, the PML clinical outcome was assessed at 12 months.
Statistical analysis. The descriptive statistics are expressed as count (percentage) for discrete variables and mean (SD) or median (range) for continuous variables. The cohort was divided into 2 groups (PLEX1 and PLEX2) according to PLEX administration. The differences between the patients who underwent PLEX and those who did not were explored with x 2 tests or Mann-Whitney U tests for categorical or continuous variables, respectively. Patients who were administered immunoadsorption were included in the PLEX1 group.
To assess the effects of PLEX and the demographic, clinical, and treatment variables on outcome after PML, univariate and multivariate Cox proportional hazards models were constructed with the 2 different outcomes, namely, overall mortality and the 4 ratings defining the patients after PML as improved or stable vs worsened or dead, considered the dependent variables. The demographic and clinical covariates that were associated with the aforementioned clinical outcomes with p values #0.10 in the univariate analysis were included in the multivariate models that included PLEX as the independent variable of interest. The multivariate models were corrected for sex and age.
Because the main objective of the present study was to analyze the association between PLEX treatment and outcome, PLEX was included in the multivariate models even if it was not statistically significant in the univariate analyses. The number of CSF-JCV copies was log-transformed due to its positively skewed distribution.
The primary research question was to evaluate whether PLEX improves survival and clinical outcomes in patients with NTZ-PML.
Level of evidence. This study provides Class III evidence that for patients with NTZ-PML, PLEX does not improve survival. Clinical severity of PML (estimated as number of signs/symptoms) at diagnosis. PLEX 5 plasmapheresis. Table 2 Univariate The study lacks the statistical precision to exclude an important benefit or harm of PLEX. DISCUSSION In recent years, PML has gained renewed attention due to reports of patients with MS who were treated with the monoclonal antibody NTZ. Because effective treatments for PML are not available, the rapid reconstitution of immune surveillance in the CNS through PLEX has been widely encouraged in order to limit viral spread. 2, 3 Adherence to this recommendation has been high worldwide, as was demonstrated by the population data gathered in this study. About 84% (184 of 219 cases) of the entire NTZ-PML cohort had been treated with PLEX, while only 16% had not. The reasons why PLEX was not administered differed in each instance (e.g., long interval between PML diagnosis and NTZ withdrawal not requiring NTZ removal, 8 first occurrences as adverse events in clinical trials, 5, 6 and lesion localization in eloquent areas, making the risk of PML-IRIS unjustifiable 11 ). This imbalance in treatment approach confirmed that PLEX was considered the treatment of choice for NTZ-PML in clinical practice, even if clinical trials supporting its efficacy in this population are lacking.
RESULTS
To fill this gap, we compared the clinical outcomes of patients with MS and NTZ-PML who were treated with PLEX with those who were not in the present study. We did not find improvement in mortality or residual disability in patients treated with PLEX compared to the untreated patients. These findings suggested that the spontaneous recovery of immunocompetence after NTZ withdrawal might counteract the spread of PML in patients with MS Table 3 Univariate and multivariate Cox hazard model analysis (using months of follow-up as the time variable) assessing the effects of plasmapheresis (PLEX) and the demographic and clinical variables on the likelihood of poor vs favorable outcomes (i.e., worsened/dead vs improved/stable) 7 In PML, the primary infection occurs in oligodendrocytes, which leads to oligodendrocyte death and demyelination. PML-IRIS develops when a massive amount of immunocompetent cells enter the CNS and localize within and at the border of visible PML lesions, where many infected oligodendrocytes are in a preapoptotic phase. These cells are the target of T-cell-mediated cytotoxicity that is elicited by immunoreconstitution and results in damage to surrounding tissues and clinical worsening. In addition, inflammation activates effector macrophages and microglia, further amplifying the inflammatory reaction and prompting blood-brain barrier damage, brain injury, and cerebral edema. 9 This immunopathologic cascade is responsible for the devastating effects that lead to great clinical disability and possibly death.
In the present study, we confirmed the negative prognosis of PML-IRIS. It is now widely accepted that the more limited the infection and earlier the diagnosis, the milder the PML-IRIS and the better the postinfectious neurologic status. 12 In our cohort, we identified 13 asymptomatic patients, and 8 of 12 were treated with PLEX, while 4 were not (information was missing for 1 patient). In this group, 5 of the treated patients remained asymptomatic, while 3 worsened, and all of the untreated (4 of 4) patients worsened. No one died. Therefore, even if the overall analysis of our cohort had shown no positive effects of PLEX on patient outcome, and the small number of asymptomatic patients did not allow for a definitive conclusion, we cannot rule out the hypothesis that the benefits of PLEX may outweigh the risks in a subgroup of patients in which the immune restoration induced by PLEX is protective and not destructive. Conversely, a slower recovery of immunocompetence following NTZ withdrawal might be a more promising strategy in patients with widespread infection at the time of diagnosis, while considering the increased risks associated with PLEX in advanced cases 13 and the long interval between oligodendrocyte infection and lysis.
In accordance with the findings of Dong-Si et al., 1 we found that older age and country of origin, namely the United States and ROW, were independently associated with poor outcome and survival. Because PLEX is equally available and applied across countries, other factors that were not evaluated in this study (e.g., time to diagnosis) might explain these results. The current study had several limitations. The main limitations were related to the retrospective structure of the analysis and the indirect collection of the clinical measures derived from the published cases. Moreover, because the datasets were created by gathering information from studies that did not have the same aim as that of the present study, the data were often incomplete (i.e., data about PLEX regimen, type of PLEX, interval between NTZ withdrawal and PML diagnosis or PLEX administration, time to death, magnetic resonance lesion volume or specific lesion location description, and neurologic status at PML-IRIS development). In our cohort, due to the limited information available, we quantified PML-IRIS as a dichotomous variable (PML-IRIS: yes/no). Therefore, we could not estimate whether PML-IRIS was more severe in patients who were treated with PLEX, which should be addressed in future studies. In addition, the need to extract meaningful clinical information led us to exclude many articles from the analysis, thus creating a potential selection bias.
Notwithstanding these limitations, our study failed to show an effect of PLEX on improving clinical outcome and survival in Italian and international patients with MS who were diagnosed with NTZ-PML. Considering the potential risks and costs of PLEX, these results argue for caution and for individualized decision-making regarding PLEX. The clinical relevance of this problem justifies the performance of prospective clinical studies in order to identify the patients who will more likely benefit from PLEX in NTZ-PML treatment.
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